Skip to main content
Log in

Ganglioside GD3 shedding by human gliomas

  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Summary

The proportion of ganglioside GD3 increases in glioma tissue and GD3 content is correlated with malignancy of gliomas. This ganglioside can be detected in the sera of patients with glioma by thin-layer chromatographic analysis.

Ganglioside GD3 was not detected in the sera of healthy donors and astrocytoma grade 2 patients. However, serum GD3 was detected in one of three astrocytoma grade 3 patients and seven of nine glioblastoma patients. These results show that shedding of GD3 increases in proportion to the degree of malignancy of gliomas. Nevertheless, all of the glioblastoma patients in this study were advanced cases. Considering the high reliability of radiological diagnostic techniques in the neurosurgical field, further study will be necessary to clarify the relationships between the GD3 level in serum and the properties of tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bernhard H, Meyer Zum Buschenfelde KH, Dippold WG (1989) Ganglioside GD3 shedding by human malignant melanoma cells. Int J Cancer 44: 155–160

    PubMed  Google Scholar 

  2. Dippold W, Knuth A, Meyer Zum Buschenfelde KH (1984) Inhabitation of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44: 806–810

    PubMed  Google Scholar 

  3. Eto Y, Shinoda S (1982) Gangliosides and neutral glycosphingolipids in human brain tumors: specificity and their significance. Advances in Experimental Medicine and Biology 152: 279–280

    PubMed  Google Scholar 

  4. Hoon DB, Irie RF, Cochran AJ (1988) Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. Cell Immunol 111: 410–419

    PubMed  Google Scholar 

  5. Houghton AL, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A Phase 1 trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242–1246

    PubMed  Google Scholar 

  6. Ladisch S, Gillard B, Wong C, Ulsh L (1983) Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 43: 3808–3813

    PubMed  Google Scholar 

  7. Ladisch S, Wu Z, Frig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenars C, Seeger R (1987) Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 39: 73–76

    PubMed  Google Scholar 

  8. Lo HS, Hogan EL, Koontz DA, Traylor TD (1980) Serum gangliosides in cerebral astrocytoma. Ann Neurol 8: 534–538

    PubMed  Google Scholar 

  9. Nakamura O, Ishihara E, Iwamori M, Nagai Y, Matsutani M, Nomura K, Takakura K (1987) Lipid composition of human malignant brain tumors. Brain and Nerve 39: 221–226

    PubMed  Google Scholar 

  10. Portoukalian J, David MJ, Shen X, Richard M, Dubreuil C (1989) Tumor size-dependent elevations of serum gangliosides in patients with head and neck. Biochem Int 18: 759–765

    PubMed  Google Scholar 

  11. Seyfried TN, Yu RK (1985) Ganglioside GD3: structure, cellular distribution and possible function. Mol Cell Biochem 68: 3–10

    PubMed  Google Scholar 

  12. Traylor TD, Hogan EL (1980) Gangliosides of human cerebral astrocytomas. J Neurochem 34: 126–131

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamura, O., Iwamori, M., Matsutani, M. et al. Ganglioside GD3 shedding by human gliomas. Acta neurochir 109, 34–36 (1991). https://doi.org/10.1007/BF01405694

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01405694

Keywords

Navigation